期刊
RADIOTHERAPY AND ONCOLOGY
卷 161, 期 -, 页码 74-82出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2021.05.022
关键词
MRI-guided radiotherapy; MR-Linac; Localized prostate cancer; Early cost-effectiveness
资金
- Netherlands Organization for Health Research and Development (ZonMw) via Innovative Medical Devices Initiative for Technology for Sustainable Healthcare [104006004]
An early health economic analysis was conducted to assess the cost-effectiveness of MR-Linac for localized prostate cancer treatment. The study found that MR-Linac was cost-effective compared to 20 and 39 fractions EBRT at baseline, but required substantial reductions in complications to be cost-effective compared to 5 fractions EBRT and LDR brachytherapy. The results were highly sensitive to the utilities of complications and the probability of biochemical progression.
Background and purpose: 1.5 Tesla magnetic resonance imaging radiotherapy linear accelerator (MR-Linac) is gaining interest for treatment of localized prostate cancer. Clinical evidence is lacking and it therefore remains uncertain whether MR-Linac is cost-effective. An early health economic analysis was performed to calculate the necessary relative reduction in complications and the maximum price of MR-Linac (5 fractions) to be cost-effective compared to 5, 20 and 39 fractionation schedules of external beam radiotherapy (EBRT) and low-dose-rate (LDR) brachytherapy. Materials and methods: A state transition model was developed for men with localized prostate cancer. Complication rates such as grade >= 2 urinary, grade >= 2 bowel and sexual complications, and utilities were based on systematic literature searches. Costs were estimated from a Dutch healthcare perspective. Threshold analyses were performed to identify the thresholds of complications and costs for MR-Linac to be cost-effective, while holding other outcomes such as biochemical progression and mortality constant. One-way sensitivity analyses were performed to outline uncertainty outcomes. Results: At is an element of 6460 per patient, no reductions in complications were needed to consider MR-Linac cost-effective compared to EBRT 20 and 39 fractions. Compared to EBRT 5 fractions and LDR brachytherapy, MR-Linac was found to be cost-effective when complications are relatively reduced by 54% and 66% respectively. Results are highly sensitive to the utilities of urinary, bowel and sexual complications and the probability of biochemical progression. Conclusions: MR-Linac is found to be cost-effective compared to 20 and 39 fractions EBRT at baseline. For MR-Linac to become cost-effective over 5 fractions EBRT and LDR brachytherapy, it has to reduce complications substantially or be offered at lower costs. (C) 2021 The Author(s). Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据